Found: 13
Select item for more details and to access through your institution.
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. 790, doi. 10.1002/ajh.26190
- By:
- Publication type:
- Article
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 3, p. 365, doi. 10.1111/ejh.14015
- By:
- Publication type:
- Article
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3‐ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 1, p. 64, doi. 10.1111/ejh.13518
- By:
- Publication type:
- Article
The management of hodgkin lymphomas in pregnancies.
- Published in:
- European Journal of Haematology, 2017, v. 99, n. 5, p. 385, doi. 10.1111/ejh.12956
- By:
- Publication type:
- Article
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 4, p. e130, doi. 10.1016/j.clml.2023.12.010
- By:
- Publication type:
- Article
Midostaurin in Combination with Intensive Chemotherapy is Safe and Associated with Improved Remission Rates and Higher Transplantation Rates in First Remission-A Multi-Center Historical Control Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S208, doi. 10.1016/j.clml.2019.07.072
- By:
- Publication type:
- Article
Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy.
- Published in:
- Palliative Medicine, 2021, v. 35, n. 5, p. 927, doi. 10.1177/02692163211000634
- By:
- Publication type:
- Article
Cardiac Disorders Associated with Cellular Therapy and Novel Agents for Acute Leukemia.
- Published in:
- Israel Medical Association Journal, 2022, v. 24, n. 3, p. 170
- By:
- Publication type:
- Article
Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 9, p. 2001, doi. 10.1007/s00277-022-04895-8
- By:
- Publication type:
- Article
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 8, p. 1719, doi. 10.1007/s00277-022-04883-y
- By:
- Publication type:
- Article
Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 3, p. 581, doi. 10.1007/s00277-021-04738-y
- By:
- Publication type:
- Article
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.
- Published in:
- 2019
- By:
- Publication type:
- journal article